“It’s hard to be a global leader in generics and not be a global leader in biosimilars,” Teva has told Generics Bulletin, as the Israeli giant pledged to “play a role in the majority of meaningful US biosimilar launches in the next five-to-eight years.”
In that timeframe, Teva expects biosimilars will have “migrated to be more like complex generics or AP-rated generics,” as automatic substitution comes into play, according to the company’s